Advertisement

Topics

The International Myeloma Foundation Company Profile

12:11 EDT 22nd March 2019 | BioPortfolio

Leading myeloma experts will discuss the latest treatment paradigms, coming out of ASH that could deliver the long-term survivors of the future, in a panel discussion moderated by Dr. Durie.


News Articles [1441 Associated News Articles listed on BioPortfolio]

Myeloma foundation to launch study to improve treatment matching

The MyDRUG study will be launched by the Multiple Myeloma Research Foundation, which will focus on assessing treatments speci -More- 

The international myeloma working group frailty score for elderly patients with multiple myeloma

Claudia Stege speaks to ecancer at the International Society of Geriatric Oncology 2018 conference in Amsterdam about the international myeloma working group frailty score for elderly patients with mu...

Foundation funding changes international reporting

(University of East Anglia) Funding by private foundations is inadvertently changing the international journalism it supports, according to a new study led by the University of East Anglia (UEA).Resea...

International Water Foundation One Drop Sets New Record Raising $8. ...

NEW YORK, Sept. 22, 2018 /PRNewswire/ -- International water foundation One Drop, in partnership with Phillips Auction House, is thrilled to announce the success of Read more...

The MMRF CoMMpass Study Drives New Discoveries in Multiple Myeloma

NORWALK, Conn., Dec. 1, 2018 /PRNewswire/ -- Today, the Multiple Myeloma Research Foundation (MMRF) announced new discoveries driven by its landmark CoMMpass StudySM into defining Read more...

Update on Meeting Professionals International Foundation Executive Director

DALLAS, Oct. 4, 2018 /PRNewswire/ -- "Effective immediately, Christine Roberts has resigned from Meeting Professionals International (MPI) Foundation. We thank Christine for her service to Read more....

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

Interim results from a large international phase III clinical trial show that adding the immunotherapy daratumumab (DARA) to standard therapy significantly extended the time before cancer got worse in...

Revlimid show significant PFS improvement in smoldering multiple myeloma

Company says drug could 'play an important role in delaying the progression of smoldering myeloma into active myeloma'

PubMed Articles [1042 Associated PubMed Articles listed on BioPortfolio]

Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.

We compared the performance of two frailty scoring systems in predicting survival among older patients with multiple myeloma: the International Myeloma Working Group (IMWG) frailty score (which includ...

Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.

Immunoglobulin D (IgD) myeloma is a rare subtype that used to lead to a poor outcome. To investigate the current clinical features, cytogenetic changes and survival of patients with IgD myeloma under ...

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In ...

Pseudohyperphosphatemia in a patient with incidentially identified progression of smoldering myeloma.

Pseudohyperphosphatemia is a rare laboratory finding in MM, especially in patients with smoldering myeloma (SMM) progressing to symptomatic multiple myeloma (MM). Laboratorians and clinicians should b...

Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.

The revised International Staging System (R-ISS) and the International Myeloma Working Group 2014 (IMWG 2014) are newer staging systems used to prognosticate multiple myeloma (MM) outcomes. We hypothe...

Clinical Trials [2603 Associated Clinical Trials listed on BioPortfolio]

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive...

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy. All eligible patients will receive immunotherapy...

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib ...

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

Primary Objectives: - Phase I: To evaluate safety and tolerability of isatuximab in Japanese patients with relapsed and refractory multiple myeloma. - Phase II: To evalu...

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

This is an international, multicenter, open-label, single-arm study for advanced Multiple Myeloma patients who had previously taken high-dose dexamethasone alone or thalidomide plus high-d...

Companies [2743 Associated Companies listed on BioPortfolio]

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The International Myeloma Foundation

Leading myeloma experts will discuss the latest treatment paradigms, coming out of ASH that could deliver the long-term survivors of the future, in a panel discussion moderated by...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The International Myeloma Foundation and the Myelodysplastic Syndromes Foundation

International Myeloma Foundation

Video of the winning moment can be found at http://www.jeopardy.com/minisites/celebrityjeopardy/

More Information about "The International Myeloma Foundation" on BioPortfolio

We have published hundreds of The International Myeloma Foundation news stories on BioPortfolio along with dozens of The International Myeloma Foundation Clinical Trials and PubMed Articles about The International Myeloma Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The International Myeloma Foundation Companies in our database. You can also find out about relevant The International Myeloma Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Myeloma
Myeloma is a malignant disease of the bone marrow. The features are an excess of abnormal malignant plasma cells in the bone marrow, lytic deposits on an X-ray and abnormal gammaglobulin in the serum.  Symptoms include tiredness and bone pain, and t...


Corporate Database Quicklinks



Searches Linking to this Company Record